Penserra Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Penserra Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2K	Hold	9	–	–	﹤0.01%	1021
2026 Q1	$2K	Hold	9	–	–	﹤0.01%	991
2025 Q4	$3K	Hold	9	–	–	﹤0.01%	934
2025 Q3	$4K	Sell	9 -3	-25%	-$1.22K	﹤0.01%	893
2025 Q2	$3K	Sell	12 -1,208	-99%	-$334K	﹤0.01%	900
2025 Q1	$329K	Buy	1,220 +1,208	+10,067%	+$310K	0.01%	657
2024 Q4	$2K	Sell	12 -2,401	-100%	-$631K	﹤0.01%	1064
2024 Q3	$663K	Sell	2,413 -8,414	-78%	-$2.19M	0.01%	493
2024 Q2	$2.63M	Buy	10,827 +10,818	+120,200%	+$1.71M	0.03%	319
2024 Q1	$1K	Hold	9	–	–	﹤0.01%	1172
2023 Q4	$1K	Hold	9	–	–	﹤0.01%	1219
2023 Q3	$1K	Buy	9 +3	+50%	+$572	﹤0.01%	1210
2023 Q2	$1K	Hold	6	–	–	﹤0.01%	1226
2023 Q1	$1K	Hold	6	–	–	﹤0.01%	1021
2022 Q4	$1K	Buy	+6	New	+$1.28K	﹤0.01%	1074
2017 Q1	–	Sell	-336	Closed	-$12K	–	557
2016 Q4	$12K	Buy	336 +70	+26%	+$2.93K	﹤0.01%	749
2016 Q3	$18K	Buy	266 +106	+66%	+$7.48K	﹤0.01%	555
2016 Q2	$9K	Buy	160 +57	+55%	+$3.59K	﹤0.01%	715
2016 Q1	$6K	Buy	+103	New	+$6.85K	﹤0.01%	574

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Penserra Capital Management's ALNY Position: Q2 2026 in Review

Penserra Capital Management held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 9 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1021.

Penserra Capital Management first reported a position in ALNY in Q1 2016 and has held it in 19 quarters since. The position peaked at $2.63M in Q2 2024. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Penserra Capital Management held 9 shares of Alnylam Pharmaceuticals worth $2K as of Q2 2026.
Penserra Capital Management left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
Alnylam Pharmaceuticals made up ﹤0.01% of Penserra Capital Management's portfolio in Q2 2026, its #1021 holding.
Penserra Capital Management first reported a position in Alnylam Pharmaceuticals in Q1 2016 and has held it in 19 quarters since.
Penserra Capital Management's Alnylam Pharmaceuticals position peaked at $2.63M in Q2 2024.
788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Penserra Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.